SELLAS Life Sciences Group, Inc. (SLS)
(Delayed Data from NSDQ)
$1.62 USD
+0.03 (1.89%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.63 +0.01 (0.62%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SLS 1.62 +0.03(1.89%)
Will SLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLS
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
Other News for SLS
Vanguard Group Inc's Strategic Acquisition in SELLAS Life Sciences Group Inc
Maxim Increases Price Target for Sellas Life Sciences (SLS) | SLS Stock News
Sellas Life Sciences price target raised by $3 at Maxim, here's why
SLS Stock: Maxim Group Raises Price Target by 75% to $7.00 | SLS Stock News
SELLAS Life Sciences (SLS) Rises on Promising AML Trial Results